Annual Interest Expense
$4.04 M
+$2.41 M+147.40%
31 December 2022
Summary:
Eagle Pharmaceuticals annual interest expense is currently $4.04 million, with the most recent change of +$2.41 million (+147.40%) on 31 December 2022. During the last 3 years, it has risen by +$1.47 million (+56.97%). EGRX annual interest expense is now at all-time high.EGRX Interest Expense Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Interest Expense
$1.45 M
-$68.00 K-4.49%
30 June 2023
Summary:
Eagle Pharmaceuticals quarterly interest expense is currently $1.45 million, with the most recent change of -$68.00 thousand (-4.49%) on 30 June 2023. EGRX quarterly interest expense is now -25.13% below its all-time high of $1.93 million, reached on 31 December 2022.EGRX Quarterly Interest Expense Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Interest Expense
$6.49 M
+$896.00 K+16.02%
30 June 2023
Summary:
Eagle Pharmaceuticals TTM interest expense is currently $6.49 million, with the most recent change of +$896.00 thousand (+16.02%) on 30 June 2023. EGRX TTM interest expense is now at all-time high.EGRX TTM Interest Expense Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EGRX Interest Expense Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +57.0% | +265.7% | +292.6% |
| 5 y5 years | +47.8% | +130.6% | +149.9% |
EGRX Interest Expense High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +147.4% | -25.1% | +295.6% | at high | +311.0% |
| 5 y | 5 years | at high | +147.4% | -25.1% | +295.6% | at high | +311.0% |
| alltime | all time | at high | >+9999.0% | -25.1% | at high | >+9999.0% |
Eagle Pharmaceuticals Interest Expense History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | $1.45 M(-4.5%) | $6.49 M(+16.0%) |
| Mar 2023 | - | $1.52 M(-21.6%) | $5.59 M(+25.9%) |
| Dec 2022 | $4.04 M(+147.4%) | $1.93 M(+21.6%) | $4.44 M(+53.0%) |
| Sept 2022 | - | $1.59 M(+188.2%) | $2.90 M(+69.9%) |
| June 2022 | - | $552.00 K(+50.8%) | $1.71 M(+8.2%) |
| Mar 2022 | - | $366.00 K(-7.3%) | $1.58 M(-3.4%) |
| Dec 2021 | $1.64 M(-36.6%) | $395.00 K(-0.3%) | $1.64 M(-1.1%) |
| Sept 2021 | - | $396.00 K(-6.2%) | $1.65 M(-5.3%) |
| June 2021 | - | $422.00 K(0.0%) | $1.75 M(-17.3%) |
| Mar 2021 | - | $422.00 K(+2.2%) | $2.11 M(-18.1%) |
| Dec 2020 | $2.58 M(-4.1%) | $413.00 K(-15.5%) | $2.58 M(-10.2%) |
| Sept 2020 | - | $489.00 K(-37.8%) | $2.87 M(-4.6%) |
| June 2020 | - | $786.00 K(-11.6%) | $3.01 M(+4.2%) |
| Mar 2020 | - | $889.00 K(+25.7%) | $2.89 M(+7.6%) |
| Dec 2019 | $2.69 M(-1.8%) | $707.00 K(+12.6%) | $2.69 M(+3.4%) |
| Sept 2019 | - | $628.00 K(-5.6%) | $2.60 M(-4.2%) |
| June 2019 | - | $665.00 K(-3.1%) | $2.71 M(-1.3%) |
| Mar 2019 | - | $686.00 K(+11.0%) | $2.75 M(+0.4%) |
| Dec 2018 | $2.74 M(+140.8%) | $618.00 K(-16.8%) | $2.74 M(+2.9%) |
| Sept 2018 | - | $743.00 K(+6.0%) | $2.66 M(+8.8%) |
| June 2018 | - | $701.00 K(+3.9%) | $2.44 M(+37.1%) |
| Mar 2018 | - | $675.00 K(+24.5%) | $1.78 M(+57.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | $1.14 M(>+9900.0%) | $542.00 K(+2.8%) | $1.14 M(+90.6%) |
| Sept 2017 | - | $527.00 K(+1217.5%) | $596.00 K(+727.8%) |
| June 2017 | - | $40.00 K(+48.1%) | $72.00 K(+105.7%) |
| Mar 2017 | - | $27.00 K(+1250.0%) | $35.00 K(+288.9%) |
| Dec 2016 | $8000.00(-27.3%) | $2000.00(-33.3%) | $9000.00(0.0%) |
| Sept 2016 | - | $3000.00(0.0%) | $9000.00(-18.2%) |
| June 2016 | - | $3000.00(+200.0%) | $11.00 K(0.0%) |
| Mar 2016 | - | $1000.00(-50.0%) | $11.00 K(0.0%) |
| Dec 2015 | $11.00 K(+37.5%) | $2000.00(-60.0%) | $11.00 K(+10.0%) |
| Sept 2015 | - | $5000.00(+66.7%) | $10.00 K(+47.1%) |
| June 2015 | - | $3000.00(+200.0%) | $6800.00(-20.9%) |
| Mar 2015 | - | $1000.00(0.0%) | $8600.00(-4.4%) |
| Dec 2014 | - | $1000.00(-44.4%) | $9000.00(+12.5%) |
| Sept 2014 | $8000.00(-99.4%) | $1800.00(-62.5%) | $8000.00(+29.0%) |
| June 2014 | - | $4800.00(+242.9%) | $6200.00(-98.6%) |
| Mar 2014 | - | $1400.00(>+9900.0%) | $453.80 K(-50.9%) |
| Dec 2013 | - | $0.00(0.0%) | $924.60 K(-34.0%) |
| Sept 2013 | $1.40 M(+353.1%) | $0.00(-100.0%) | $1.40 M(0.0%) |
| June 2013 | - | $452.40 K(-4.2%) | $1.40 M(+47.7%) |
| Mar 2013 | - | $472.20 K(-0.7%) | $947.60 K(+99.3%) |
| Dec 2012 | - | $475.40 K | $475.40 K |
| Sept 2012 | $309.00 K | - | - |
FAQ
- What is Eagle Pharmaceuticals annual interest expense?
- What is the all time high annual interest expense for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals quarterly interest expense?
- What is the all time high quarterly interest expense for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals TTM interest expense?
- What is the all time high TTM interest expense for Eagle Pharmaceuticals?
What is Eagle Pharmaceuticals annual interest expense?
The current annual interest expense of EGRX is $4.04 M
What is the all time high annual interest expense for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high annual interest expense is $4.04 M
What is Eagle Pharmaceuticals quarterly interest expense?
The current quarterly interest expense of EGRX is $1.45 M
What is the all time high quarterly interest expense for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high quarterly interest expense is $1.93 M
What is Eagle Pharmaceuticals TTM interest expense?
The current TTM interest expense of EGRX is $6.49 M
What is the all time high TTM interest expense for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high TTM interest expense is $6.49 M